Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Pengcheng Wang *Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766.ORCID 0000-0001-6432-669X
Kristan H Cleveland *Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766.
Ayaz Shahid *Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766.
Chathurika Rathnayaka *Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766.ORCID 0000-0001-5132-2219
Farideh AmirradDepartment of Pharmaceutical Sciences, Marshall B. Ketchum University, Fullerton, CA 92831.
Zhenpeng SongLibin Cardiovascular Institute, Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.ORCID 0000-0003-3084-1356
John Paul EstilloreLibin Cardiovascular Institute, Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
Ruiwu WangLibin Cardiovascular Institute, Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
Thomas G BackDepartment of Chemistry, University of Calgary, Calgary, AB T2N 1N4, Canada.ORCID 0000-0002-3790-1422
S R Wayne ChenLibin Cardiovascular Institute, Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.ORCID 0000-0001-5808-0304
Ying HuangDepartment of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766.ORCID 0000-0003-4756-7939
Funding
Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilolR01CA269653 · NCI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI Ying Huang · 2022 to 2026
$1.6M
Topical delivery of non-β-blocking R-carvedilol for prevention of UV-induced skin cancerR15CA227946 · NCI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI HUANG, YING · 2018 to 2018
$409k
Chemoprevention of lung cancer with the β-blocker carvedilolR03CA256241 · NCI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI HUANG, YING · 2021 to 2022
$141k
HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (DCP, NCI) R01CA269653HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (DCP, NCI) R15CA227946NCI NIH HHS R01 CA269653NCI NIH HHS R03 CA256241NCI NIH HHS R15 CA227946
6 · The paper itself
Abstract
Epidermal growth factor (EGF) induces anchorage-independent growth in promotion-sensitive (P
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Potentiation of ryanodine receptor-mediated calcium release by MAPK is responsible for epidermal transformation and carcinogenesis. · full record | Socratic